Today's Stock Investing Pulse
Devon Energy eyes $8B offer as Stone Ridge targets Marcellus assets post‑merger
Devon Energy completed its merger with Coterra, creating a larger oil and gas operator. Stone Ridge Asset Management signaled interest in Devon’s Marcellus assets with an $8 billion opening offer, and the combined company expects to lift its dividend by roughly 30 %.
JinkoSolar Q4 2025 Earnings Call Shows 26 GW Shipments but Margin Collapse
JinkoSolar announced $2.5 billion in Q4 2025 revenue and shipped 26 GW of modules, but gross margin fell to 0.3% and adjusted net loss widened to roughly $120 million. The company’s net debt jumped to $3.44 billion, underscoring pressure from raw‑material costs and a shifting market mix.
Entain Posts 3% Q1 Net Gaming Revenue Rise, Volume Up 8%
Entain PLC announced a 3% increase in first‑quarter net gaming revenue and an 8% jump in betting volume, signalling renewed strength in its diversified online gambling portfolio. The company reaffirmed its FY2026 EBITDA target of £1.131 billion (≈$1.44 billion).
Apple Continues to Gain Market Share in China. Here's What It Means for Investors.
Apple’s iPhone shipments in China surged 20% year‑over‑year in Q1, lifting its market share to 22% and outpacing rivals like Huawei and Vivo, which only grew 2%. The growth comes as overall Chinese smartphone shipments fell 4%, highlighting Apple’s resilience...
Track Normalized FCF/Share via Long‑Term Cycle Analytics
This is a great question One of the most important output metrics in any model, in my opinion, is normalized FCF/share. There are many assumptions that lead to your FCF/share metric, including revenue & normalized margin assumptions. But quarter to quarter and year...
Top Bank Revamps Apple Stock Price Target
BNP Paribas upgraded Apple (NASDAQ:AAPL) to Outperform from Neutral and raised its price target to $300. The bank cited Apple’s scale, premium product mix, and strong supply‑chain control as buffers against a rising memory‑price crunch that could suppress lower‑ and mid‑tier...
AI Could Transform SNDK Into High‑Growth Memory Leader
Is $SNDK a cyclical memory stock, or will AI make memory a stable grower? $SNDK +2,838% 1Y 🚀 +234% YTD 🟢 - Weak Margins - Weak Growth since 2022 - INSANE Outlook from AI - 157% 2028 FCF CAGR - Reasonable Valuation - 1% Above Consensus Price...
Economic Commentary Q2 2026: Markets Reawaken to Risk
Ron Albahary, CIO of LNW Advisors, released the firm’s Q2 2026 Economic Commentary, noting that markets are reawakening to risk after a period of caution. The report cites renewed inflation pressures, heightened geopolitical shocks, and rapid AI‑driven disruption as key...
Bank of America Raises Apple Price Target to $325 From $320
Bank of America increased its price target for Apple Inc. to $325, up $5 from the prior $320, while maintaining a Buy rating ahead of the company’s fiscal Q2 earnings. BofA projects Q2 revenue of $113 billion and earnings per share...
Tesla, SpaceX Poised for 50/50 Merger of Equals
After further research and our discussions on the @cyberbulls with @TeslaLarry yesterday, I agree that this will very well be a Merger of Equals. BUT - in my opinion - it will not be at the then stock price, which is...
2 ETF Smart Leverage Portfolio Could Beat The S&P 500 By 200% Over 25 Years
A new research note proposes a two‑ETF smart‑leverage strategy that could outpace the S&P 500 by roughly 200 % over the next 25 years. The method blends a core equity ETF with a leveraged counterpart, applying higher exposure only when market conditions are...
UnitedHealth Group: Poised To Challenge The $360 Resistance
UnitedHealth Group is positioned for a strong margin rebound, with first‑quarter 2026 earnings per share forecast at $6.62 and net margin climbing to 5.53%. The company’s strategic repricing, AI‑enabled cost efficiencies, and a 2.48% increase in Medicare Advantage rates underpin...
Microsoft: Don't Buy The Dip, A 30% Correction Is Still Ahead
Microsoft (MSFT) has been downgraded to a Sell rating as analysts forecast a roughly 30% price correction. The downgrade stems from an aggressive capital‑expenditure plan that could reach 33% of revenue by 2026, shifting the firm from high‑margin software to...
Flexible Solutions International, Inc. (FSI) Q4 2025 Earnings Call Transcript
Flexible Solutions International’s CEO Dan O’Brien used the Q4 2025 earnings call to highlight a strategic pivot in its NanoChem (NCS) division, which now generates the bulk of the company’s revenue. NCS launched food‑grade operations in 2022 and is on track...
Arxis: Critical (Aerospace) Provider Flies Off
Arxis debuted on the NYSE with a 39% first‑day jump, pushing its market cap to roughly $17 billion. The company follows a TransDigm‑style roll‑up model, targeting mission‑critical aerospace components through acquisitions, pricing leverage, and operational efficiencies. Despite the lofty valuation—about 10×...
Average Returns Mislead; Index Funds Beat Most Stocks
𝐓𝐡𝐞 𝐟𝐢𝐧𝐚𝐧𝐜𝐞 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧 𝐡𝐚𝐬 𝐚 𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐛𝐥𝐞𝐦. New research from Hendrik Bessembinder argues that the standard tools, arithmetic means, Sharpe ratios, alphas, paint a misleadingly rosy picture of stock picking. Think of it like lottery tickets. The odds of winning "any prize"...
EVgo: It Is Getting Very Attractive As Operations Nearing Breakeven
EVgo, Inc. reported a 49% year‑over‑year revenue surge in FY 2025, driven by strong ancillary and charging‑segment sales. The company posted positive adjusted EBITDA of $25 million in Q4 and lifted its gross margin to 46%, while holding $151 million in cash against...
Ubisoft: An Opportunity Lies Hidden Under Years Of Underperformance
Ubisoft Entertainment has suffered years of underperformance due to over‑hiring and questionable managerial choices, prompting a costly internal re‑organization. The company now trades at roughly three times its 2023 earnings, a distressed multiple that reflects both recent losses and market...
How Momentum ETF MFMO Has Outpaced Rivals & Volatility YTD
Momentum factor ETFs have emerged as strong satellite options amid a tech‑heavy, volatile market. The Motley Fool Momentum Factor ETF (MFMO) posted a 6.46% year‑to‑date gain since its December launch, outpacing Fidelity’s Momentum Factor ETF (FDMO), which delivered a 38.28%...
Berkshire Gives Acquisitions Freedom, Not Just Capital
The most underrated thing Berkshire offers its acquisitions isn't capital. It's freedom. 1️⃣ No committee theatrics eating up your calendar 2️⃣ No quarterly PowerPoint ritual nobody believes in 3️⃣ No second-guessing where your excess cash goes Just: run the business. We'll handle the rest. Most investors...
IDV: Ex-U.S. Remains A Superior Income Proposition
iShares International Select Dividend ETF (IDV) delivers a trailing dividend yield of about 4.58% and a SEC yield near 5.11%, driven by high‑dividend, cash‑generative companies in developed ex‑U.S. markets. Valuation gaps remain wide, with non‑U.S. equities trading at materially lower...
Beating the S&P Is the Only
What people don't understand about the S&P is that every single person in the country who has money is also invested in it When your money goes up 15%, so does everyone else's You gained zero relative wealth. You need to outperform...
This Biopharma Stock Could More than Double on Oral Eczema Treatment, Goldman Sachs Says
Goldman Sachs has initiated coverage of Corvus Pharmaceuticals with a buy rating and a $40 price target, implying a 166% upside from the recent close. The firm’s optimism centers on soquelitinib, an oral non‑steroidal drug targeting atopic dermatitis, which achieved...
Greg Abel Concentrates 79% of Berkshire's $318B Portfolio in Ten Stocks
Greg Abel, Berkshire Hathaway's new CEO, has allocated $251 billion—79% of the conglomerate's $318 billion investment portfolio—to just ten stocks, led by Apple and American Express. The move revives a long‑standing concentration strategy and forces wealth managers to reassess risk exposure for...
Fidelity Flags Critical Flaws in the Bull Market
Fidelity’s 2026 stock market outlook warns that the bull market’s headline gains conceal significant weaknesses. While the cap‑weighted S&P 500 has risen about 91% since October 2022, an equal‑weight view shows only a 52% gain, highlighting the outsized role of the Magnificent 7....
Yuanjie Semiconductor Tops Moutai as China’s Priciest Listed Stock at ¥1,439 ($200)
Yuanjie Semiconductor Technology Co. surged 9.6% to an all‑time high of ¥1,439 ($200) on Friday, eclipsing Kweichow Moutai and becoming the most expensive stock on China’s mainland exchanges. The jump reflects growing investor appetite for advanced photonic chip makers as...
Decibel Cannabis Posts 22% Revenue Growth to $113M, Unveils Aggressive Go‑to‑Market Plan
Decibel Cannabis Company announced FY2025 net revenue of $113 million, a 22% increase year‑over‑year, and outlined a multi‑pronged go‑to‑market strategy. The company highlighted a 484% jump in international sales, a new Standard Issue brand, and a debt refinance that positions it...
Independent Bank (INDB) Earnings Call Transcript
Independent Bank reported Q1 2026 GAAP net income of $79.9 million, EPS $1.63 and a 3.9% net interest margin, while returning $94 million to shareholders and raising the quarterly dividend 8.5% to $0.64. The bank reduced its office‑related commercial real‑estate exposure by $56 million,...
WESPAC Advisors Puts $5.7 Million Into JPMorgan International Value ETF
WESPAC Advisors SoCal, LLC disclosed a new $5.71 million position in JPMorgan International Value ETF (JIVE), acquiring 66,248 shares. The stake accounts for about 1.21% of the firm’s reportable assets, highlighting a fresh institutional vote for international value stocks as the...
Travelers Posts $1.7B Q1 Profit, Boosts Dividend and Share Buybacks
Travelers Companies posted a $1.7 billion core profit for Q1 2026, lifted its dividend by 14% to $1.25 per share and returned over $2.2 billion to shareholders. The results were driven by $1.2 billion underwriting income, lower catastrophe losses and a 9% rise...
ChinaAMC Fund Up 15% YTD, Beats 98% Peers on AI and Healthcare Bets
China Asset Management Co.'s China Opportunities Fund jumped 15% this year, outperforming 98% of its peers. The fund’s heavy tilt toward AI‑chain companies and healthcare is driving the outperformance while broader Chinese indices lag.
Deep Cash‑Flow Modeling Beats EPS for True Value
The senior analyst at a Tiger Cub who trained me on financial modeling back in '08 (shoutout Chris Laporte) walked me through the importance of deeply detailed cash flow builds. So much of the world is focused on EPS (certainly...
Morgan Stanley Resets Palantir Stock Forecast
Morgan Stanley reaffirmed its $205 price target for Palantir, translating to roughly 44% upside from the current $142 share price. The bank kept its equal‑weight rating while noting the stock could modestly accelerate growth and raise full‑year guidance ahead of...
Half of Global Markets Rebound Amid Iran Conflict
"Looking across 46 different country ETFs since the start of the Iran war, the global picture looks far more resilient than headlines and the chattering media's pundits would suggest. Nearly half of the world's major markets -- 20 out of...
Foreign Value Stocks Surge, Advisors Finally Warm Up
After being up around 30% last year, foreign/emerging value is up another 15-20% this year. You're seeing the narrative shift with advisors a bit, ever so slightly. It seems to be moving from "don't even bring up foreign stocks, they've underperformed...
Evercore Maintains Positive Stance on MeiraGTx Holdings Plc (MGTX) Amid Sector Revisions
Evercore ISI analyst Gavin Clark‑Gartner lowered MeiraGTx Holdings plc’s price target to $18 from $20 while retaining an Outperform rating. The adjustment was part of a sector‑wide review of small‑ and mid‑cap biotech firms ahead of second‑quarter catalysts. Earlier this...
Oil Dip to $60 Could Lift S&P 10%
While oil gurus and geopolitical experts were opining with confidence on the potential outcomes we said we don't know shit. Here is our DSR from 3/22. https://t.co/268Hkj6EKA Herein we just considered scenarios and how they play out in macro based...
Netflix's EPS Beat Fueled by Breakup Fee, Not Growth
Netflix 'crushed' earnings last night: $1.23 EPS vs $0.76 expected, a 60% beat. Revenue $12.25B, up 16% year over year. The stock is down 10% today at $97. Why? Because the beat was fake. $2.8B of that EPS came from...
Morgan Stanley Updates Bicycle Therapeutics Plc (BCYC) Outlook Amid Pipeline Refocus
Morgan Stanley lowered its price target for Bicycle Therapeutics plc (BCYC) to $12 from $13, while maintaining an Equal Weight rating, reflecting a revised valuation after the company refocused its pipeline on BT5528 and next‑generation Bicycle conjugate programs. The shift...
Equity Risk Premium Near 4% Validates Current Valuations
With credit spreads still well-behaved and operating margins making new highs by the week, the valuation picture for US stocks remains justified, especially after the drawdown of the past few weeks. The chart below shows that the “fitted” equity risk...
Industrials Forward P/E Near Record Highs vs Market
The forward P/E of the industrials sector relative to that of the broader market remains near record highs. ty @augurinfinity https://t.co/XZoDHelWSz https://t.co/doqKhFeI1Y
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
Jefferies lowered its price target for Arbutus Biopharma (ABUS) to $5.50 from $7.00, citing a higher probability that Moderna will win its appeal in a patent dispute. The outcome affects a potential $1.3 billion contingent payment tied to the case, while...
North Asia EPS Upgrade Raises MSCI EM Forecast
GS: Upgrades to North Asia EPS growth push our 2026/27 MSCI EM EPS growth forecast to 34%/14% from 23%/13% https://t.co/jK4UGxp0LY
Yardeni Cites Three Reasons Fueling Equity Optimism
Ed Yardeni lays out three reasons for optimism on equities and explains what's bringing back enthusiasm for the tech sector. https://t.co/0YEftxPkN4
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
Mizuho Securities raised its price target on Corbus Pharmaceuticals (CRBP) to $40 from $39 and kept an Outperform rating after the company’s Q4 results. The broker noted the stock is trading close to Corbus’s cash balance, implying limited downside risk....
AI Threatens Tech Moats, Future Cashflow Valuations Collapse
If AI lives up to the hype, it will erode the traditional long term moats of technology companies. As a result, no one with a brain wants to pay for cashflows far in the future. These multiples cannot come back unless...
NVDA Overvalued, META Crowned 2026 Top Pick
$NVDA was obviously mispriced. $META was a Futurum Equities 2026 best idea for a reason. 🚀
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
Jefferies downgraded Replimune Group (NASDAQ:REPL) from Buy to Hold and slashed its price target to $2 after the FDA issued a complete response letter on the RP1 oncolytic therapy. The FDA’s feedback diverged from earlier Type A meeting guidance, raising...
Geopolitical Tensions Revive Value Investing, Future Uncertain
This week in value: The Iran War Has Fired Up Value Investing. But What Next? (Bloomberg) A century of value investing (IFA) Why Value Investing Works (And Why It Has to Stop Working First) (Safal) Third Avenue Management: Small-Cap Value Strategy Overview and Insights...
Evercore Adjusts Fortrea Holdings Inc. (FTRE) Valuation Following Updated Near-Term Assumptions
Evercore ISI trimmed Fortrea Holdings (FTRE) price target to $14 from $25 while keeping an Outperform rating, citing revised near‑term assumptions in its Q1 healthcare technology update. The change coincides with FTRE’s launch of Fortrea Intelligent Technology (FIT), an AI‑enabled...
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Wolfe Research has initiated coverage of Palisade Bio (NASDAQ:PALI) with an Outperform rating and a $7 price target, signaling confidence in the company’s long‑term prospects despite limited near‑term activity. The firm highlighted Phase 1b data for the oral PDE4 prodrug PALI‑2108,...